Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis

Liver International

Volumn 25, Issue 4, 2005, Pages 760-771

  Younossi, Zobair M ^a,b   Gorreta, Francesco ^b   Ong, Janus P ^a,b   Schlauch, Karen ^a,b   Del Giacco, Luca ^b   Elariny, Hazem ^a,b   VanMeter, Amy ^b   Younoszai, Abraham ^a,b   Goodman, Zachary ^c   Baranova, Anna ^b   Christensen, Alan ^b   Grant, Geraldine ^b   Chandhoke, Vikas ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Gene expression; Micro arrays; NASH

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ADRENOMEDULLIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE ISOENZYME 1; CALGRANULIN; CATALASE; CHITINASE; CHOLESTEROL; COMPLEMENTARY DNA; FIBRINOGEN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; INSULIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 3; LONG CHAIN FATTY ACID COENZYME A LIGASE; NICOTINAMIDE METHYLTRANSFERASE; NUCLEAR FACTOR; ORNITHINE DECARBOXYLASE; SCRAMBLASE; SERINE DEHYDRATASE; SERINE PROTEINASE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SYNDECAN 4; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; ZINC FINGER PROTEIN;

ADULT; APOPTOSIS; BARIATRIC SURGERY; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DIET RESTRICTION; DNA MICROARRAY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIVER BIOPSY; LIVER REGENERATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FATTY LIVER; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS; HUMANS; LIVER; MALE; MIDDLE AGED; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VIRGINIA;

EID: 22844439963     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01117.x     Document Type: Review

References (71)

1. Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
2. Falck-Ytter Y, Younossi Z M, Marchesini G, McCullough A J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
3. Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
4. Younossi Z M, Diehl A M, Ong J P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52.
5. Younossi Z M. Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1999; 1: 57-62.
6. Younossi Z M, Gramlich T, Liu Y C, Matteoni C, Petrelli M, Goldblum J, Ryricki L, McCullough A J. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560.
7. Reid A E. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
8. Burt A D, Mutton A, Day C P. Diagnosis and interpretation of steatosis and steatohepatitis. Sem Diagn Pathol 1998; 15: 246-58.
9. Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
10. Lee R G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-8.
11. Teli M R, James O F, Burt A D, Bennett M K, Day C P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
12. Day C P, James O F W. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
13. James O F, Day C P. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
14. Powell E E, Cooksley W G, Hanson R, Searle J, Halliday J W, Powell L W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
15. Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
16. Caldwell S H, Oelsner D H, Iezzoni J C, Hespenheide E E, Battle E H, Driscoll C J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
17. Ong J, Younossi Z M, Reddy V, Price L L, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
18. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
19. Hay J E, Czaja A J, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193-7.
20. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811-6.
21. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 143-9.
22. Hulcrantz R, Glaumann H, Lindberg G, Nilsen L H. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21: 109-13.
23. Araujo L M B, DeOliveira A, Nunes D S. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metabolism 1998; 24: 458-62.
24. El-Hassan A Y, Ibrahim E M, Al-Mulhim F A, Nabhan A A, Chammas M Y. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992; 65: 774-8.
25. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992; 27: 521-8.
26. Daniel S, Ben-Menachem T, Vasudevan G, Ma C K, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
27. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
28. Lonardo A, Bellino M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a 'bright' liver echo pattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6.
29. Brolin R E, Bradley L J, Taliwal R V. Unsuspected cirrhosis discovered during obesity operations. Arch Surg 1998; 133: 84-8.
30. Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
31. Younossi Z, Gramlich T, Matteoni C, Boparai N, McCullough A. Non-alcoholic fatty liver disease in patients with type II. Diabetes Clin Gastro Hepatol 2004; 2(3): 262-5.
32. Chitturi S, Farrell G C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
33. Weltman M D, Farrell G C, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
34. Tilg H, Diehl A M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
35. Raucy J L, Lasker J M, Kraner J C, Salazar D E, Lieber C S, Corcoran G B. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991; 39: 275-80.
36. Zhang C, Walker L M, Hinson J A, Mayeux P R. Oxidant stress in rat liver after lipopolysaccharide administration: effect of inducible nitric-oxide synthase inhibition. J Pharmacol Exp Ther 2000; 293: 968-72.
37. Leclercq I A, Farrell G C, Field J, Bell D R, Gonzalez F J, Robertson G R. Cyp2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
38. Weltman M D, Farrell G C, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
39. Fong D G, Nehra V, Lindor K D, Buchman A L. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
40. Rashid A, Wu T C, Huang C C, Chen C H, Lin H Z, Yang S Q, Lee F Y, Diehl A M. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999; 29: 1131-8.
41. Gramlich T, Kleiner D, McCullough A, Matteoni C, Boparai N, Younossi Z M. Pathologic features associated with fibrosis in non-alcoholic fatty liver disease. Human Pathol 2004; 35(2): 196-9.
42. George D K, Goldwurm S, MacDonald G A, Cowley L L, Walker N I, Ward P J, Jazwinska E C, Powell L W. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
43. Younossi Z M, Gramlich T, Bacon B R, Matteoni C A, Boparai N, O'Neill R, McCullough A J. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
44. Ong J P, Younossi Z M, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21: 266-71.
45. Guttmacher A E, Collins F S. Genomic medicine - a primer. N Engl J Med 2002; 347: 1512-20.
46. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001; 120: 955-66.
47. Collins F S, Guttmacher A E. Genetics moves into the medical mainstream. JAMA 2001; 286: 2322-4.
48. Dessein P H, Joffe B I, Stanwix A E, Botha A S, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002; 29: 462-6.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
50. Epstein C B, Hale IV W, Butow R. Numerical methods for handling uncertainty in microarray data: an example analyzing perturbed mitochondrial function in yeast. Methods Cell Biol 2001; 65: 439-52.
51. Ward J H. Hierarchical grouping to optimize an objective function. J Am Stat Assoc 1963; 58: 236-44.
52. Eisen M B, Spellman P T, Brown P O, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8.
53. Grace M B, McLeland C B, Gagliardi S J, Smith J M, Jackson W E I, Blakely W F. Quantitative RT-PCR assay using simultaneous measurement of four fluorosphores for radiation-responsive gene targets. Clin Chem 2003; 49: 1467-75.
54. Fausto G. HEGARDT. Mitochondrial 3-hydroxy-3-methyl-glutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J 1999; 338: 569-82 (printed in Great Britain) 569.
55. Sanyal A J, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120(5): 1183-92.
56. Gargiulo C E, Stuhlsatz-Krouper S M, Schaffter J E. Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane. J Lipid Res 1999; 40(5): 881-92.
57. Hertz R, Magenheim J, Berman I, Bar-Tana J. Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4α. Nature 1998; 392: 2.
58. Magee T R, Cai Y, El-Houseini M E, Locker J. J Biol Chem 1998; 273(45): 30024-32.
59. Lazarevich N L. Molecular mechanisms of alpha-fetoprotein gene expression. Biochemistry (Mosc) 2000; 65(1): 117-33.
60. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123(1): 134-40.
61. Dong J M, Nordloh P W, Chiu J F. The mechanism of the bidirectional regulation of the rat alpha-fetoprotein gene by glucocorticoid hormone. Mol Cell Endocrinol 1989; 66(1): 109-14.
62. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244-51.
63. Bensadoun E S, Burke A K, Hogg J C, Roberts C R. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 1996 Dec; 154(6 Part 1): 1819-28.
64. Szende B, Lapis K, Kovalszky I, Timar F. Role of the modified (glycosaminoglycan producing) perisinusoidal fibroblasts in the CCl4-induced fibrosis of the rat liver. In Vivo 1992; 6(4): 355-61.
65. Benyon R C, Arthur M J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21(3): 373-84.
66. Leu J I, Crissey M A, Taub R. Massive hepatic apoptosis associated with TGF-beta1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice. J Clin Invest 2003; 111: 129-39.
67. Hai T, Wolfgang C D, Marsee D K, Allen A E, Sivaprasad U. ATF3 and stress responses. Gene Exp 1999; 7: 321-35.
68. Yang S Q, Lin H Z, Mandal A K, Huang J, Diehl A M. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694-706.
69. Irshad M, Chaudhuri P S. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol 2002; 40(11): 1233-9.
70. Mari M, Cederbaum A I. Induction of catalase, alpha, and microsomal glutathione S-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress. Hepatology 2001; 33(3): 652-61.
71. Hurteau G J, Spivack S D. mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. Anal Biochem 2002; 307: 304-15.